This study focuses on individuals who have memory problems that are consistent with early Alzheimer's disease. The purpose of the study is to evaluate the safety and potential benefit of an oral investigational drug called varoglutamstat (PQ912) in Alzheimer’s disease. The study aims to identify the best dose of varoglutamstat and determine whether it delays or slows the progression of the symptoms of early Alzheimer’s disease by targeting amyloid, one of the proteins that accumulates in the brains of people with Alzheimer’s disease. Participants will be randomly assigned to receive either varoglutamstat or placebo (inactive substance).
What is the full name of this clinical trial?
A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat in Patients with Early Alzheimer's Disease with a Stage Gate to Phase 2B